Patients lose access to lifesaving therapies when governments impose drug price controls, and the consequences are measured in delayed treatment, depleted research pipelines and lives cut short, according to a new research analysis from the Information Technology and Innovation Foundation (ITIF). ITIF examined how European drug pricing policies drove the continent's fall from global biopharmaceutical leadership. While compiling and assessing existing research on the patient impact, the...

February 25, 2026 (WASHINGTON, D.C.)  — The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the State of the Union address, during which President Trump supported codifying “Most Favored Nation” (MFN) drug pricing: “The 194 million Americans living with multiple chronic conditions depend on consistent, timely access to the therapies that help manage their health. Ensuring these treatments are affordable is a goal PFCD strongly supports, and one that...

February 4, 2026 (WASHINGTON, D.C.)  The Partnership to Fight Chronic Disease (PFCD) applauds the passage of the Consolidated Appropriations Act of 2026 and its inclusion of many important health care elements that support efforts to better prevent and manage costly chronic conditions. Notably, the bill will increase transparency and lower health care costs for people living with one or more chronic conditions by instituting much needed reforms for pharmacy benefit managers (PBMs) in both...